Emergent BioSolutions | EBS - مصاريف البيع والإدارة





مصاريف البيع والإدارة تغيير تاريخ
Acadia Pharmaceuticals USD 148.57M 12.22M 2026-06
Akebia Therapeutics USD 23.53M 3.19M 2025-12
ALKERMES USD 196.64M 67.96M 2026-06
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
Amarin USD 18.97M 1.03M 2025-12
ANI Pharmaceuticals USD 91.66M 18.01M 2026-06
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Coherus Biosciences USD 15M 6.26M 2025-12
Emergent BioSolutions USD 182.8M 82.3M 2023-06
Exelixis USD 147.63M 8.03M 2026-06
Glaxosmithkline GBP 2.12B 1.44B 2026-03
Heron Therapeutics USD 23.74M 605K 2025-12
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
Lexicon Pharmaceuticals USD 3.98M 195K 2025-12
Merck USD 2.89B 219M 2026-06
Moderna USD 216M 43M 2026-06
Myriad Genetics USD 122.3M 6.7M 2025-12
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Pacira USD 91.81M 7.93M 2026-06
Pfizer USD 3.41B 496M 2026-06
PTC Therapeutics USD 73.89M 13.31M 2026-03
Sanofi EUR 2.63B 307M 2026-06
Sarepta Therapeutics USD 107.6M 53.57M 2026-06
United Therapeutics USD 206.7M 50.1M 2026-06
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12